Innovation that Matters

Filter By


Delivering on the Promise of New Modalities: An Interview with Daniel Getts, CEO, Co-Founder & Board Director of Myeloid Therapeutics

As part of WuXi AppTec’s ongoing efforts to collaboratively foster new thinking and actionable approaches in advancing breakthroughs for patients, we have launched a new interview series in 2022 – “Delivering on the Promise of New Modalities” – so leading voices of R&D can share how their approaches are addressing the barriers standing in the way of breakthroughs. Our next interview in this series features Daniel Getts, CEO, Co-Founder & Board Director of Myeloid Therapeutics, a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune diseases. Myeloid has recently entered into strategic partnerships with Prime Medicine and Acuitas, and launched with $50 million in financing just last year. Myeloid Therapeutics’ proprietary platform provides clinical solutions that match therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. Thanks for taking the time to join us, Daniel! For developing cancer and autoimmune disease treatments, what are the challenges for the industry? What’s your approach? Daniel: Myeloid tackles very difficult, high unmet medical need indications like PTCL, liver cancer and glioblastoma. In these cancer types, the industry-wide challenges to solving these diseases have been finding an efficacious and safe therapeutic modality, and then successfully delivering a drug to these tumor types. At Myeloid, we use a broad range of cell and gene therapy approaches to tackle these historically challenging indications. In cell therapy, the field has experienced tremendous success with multiple approved therapies over the last decade, but limitations of the first-generation products exist with problems in manufacturing cost-effective, scalable, editable therapies that can be used for a wide range of patients. These approaches have also not been shown to impact the treatment of solid tumors and we are working towards a breakthrough outcome in major tumor types. Myeloid’s next-generation technologies, in particular our in vivo reprogramming, novel CARs and gene-editing, hold the potential to deliver clinical breakthroughs by harnessing a full immune response and expanding upon the industry lessons learned from earlier technologies and approaches. Your company is working on several new modalities like cell therapy and cell programming. What’s the novelty? How are they different from existing approaches? Daniel: At Myeloid, we deploy novel mRNA-based CAR therapies to shift the treatment paradigm for cancer and many autoimmune diseases. Our CARs can be delivered by a range of methods, as clinical and disease circumstances warrant, whether as autologous cells, allogeneic cells, or in vivo direct reprogramming of targeted cells. This approach shows a broad immune response and indications of heating the tumor microenvironment (TME). I have a very strong belief that we can make a significant step forward with this bold vision someday soon, by continuing to accelerate our technology and clinical approaches to treatment, including in combination with adaptive cell therapies. As an immunologist by training, I recognize that leveraging the immune system holds the potential to treat a long list of diseases, and this is what we’ve prioritized at Myeloid. Our therapies and targeted cells promote direct tumor-killing, infiltration and tumor microenvironment remodeling. These approaches promote proinflammatory cytokines to combat tumor suppressive factors, and present neoantigens for uptake and cross-present antigen to T cells, which suggest that our targeting of the myeloid compartment sets us apart from others in the field. By integrating knowledge from the fields of RNA biology, immunology, and medicine, we have created a proprietary platform that can be tailored for the clinical indication and patient needs. The breadth and depth of our platform present Myeloid as an emerging leader in immunology. Do you see any challenges in realizing the full potential of your technologies? What’s your strategy to solve them? Daniel: The proprietary data derived from Myeloid technologies gives us continued conviction that we are on a path to create a significant impact on patients’ lives and the field of immunology. We’ve made tremendous progress in a short amount of time, particularly a function of the technology scalability and resulting from operational execution. We are a clinical-stage company and we were the first company to dose a patient with a novel mRNA CAR monocyte therapy; we have presented preclinical data at AACR 2022 demonstrating the potential for our technology to program cells directly in vivo, representing a highly-disruptive approach to new product realization. We have partnered with solid companies, like Acuitas and Prime Medicine, to de-risk our pipeline and bring these therapies to the next level for patients. Over the next several years, we expect to continue managing a portfolio, with a priority on the development of our in vivo programming approaches, advancing our next-gen CARs, and accelerating our portfolio through key enabling collaborations. To ensure future success towards these ambitious goals, we, like all emerging growth biotechs, face multiple challenges . We view this as healthy and are confident that our track record of innovation will see Myeloid emerge stronger and well-positioned within the next growth stage of the sector. As this sector recalibration occurs, we are mindful of methods to advance our assets within creative collaborations, and ultimately, we are keeping our eye on getting these therapies to patients, on a global basis, and as soon as feasible. COVID has altered the pharma/biotech industry. What are some of the lessons learned now that potentially we can apply to the challenges that we’re talking about today? Daniel: COVID changed the biotech industry in monumental ways. My office window looks directly onto the Moderna headquarters across the street and I feel inspired every day thinking about the innovations made to create multiple vaccines within a short amount of time. The entire world was looking towards the biotech sector for new product innovation, waiting for clinical solutions to blunt or mitigate the magnitude of diseases. Multiple companies delivered meaningful advances for society, but also to catalyze interest in technologies that had not been harnessed fully, like mRNA, LNPs, or other novel delivery approaches. We have never seen anything like what happened during COVID in the last 100 years – it was nothing short of remarkable and it inspired many companies in our industry to challenge working assumptions, deploy faster, and more creatively. It also demonstrated that collaboration is key – when a collective goal is on the horizon, (e.g., to find a vaccine for a deadly infectious disease), industry constituents brought together and integrated key technologies into new products. They rose to a unique challenge, together, to improve human health. Ultimately, that is our job – as an industrial sector and certainly at Myeloid –to find solutions for patients, sooner. We accomplish more together. Thanks for your insights. Let’s talk about future before we close. In your opinion, what could be the next big scientific breakthrough in the life science industry? Daniel: My expectation is that the next big scientific breakthrough, by which I mean disruptive and transformative for patients and across industry competitive dynamics, may actually come from some of what we are working on at Myeloid – in vivo reprogramming of innate immunity for difficult to treat diseases. The rationale for in vivo reprogramming arises from the challenges associated with the development of ex vivo cell therapies – manufacturability, scalability and the risk of immune rejection. Despite progression toward 1 day manufacturing & allogenic approaches, challenges remain – e.g., the need to replicate in vivo microenvironments for cells within in vitro conditions and to process variation between cell type, indications or disease areas. Whilst we balance the natural potential of autologous cells at Myeloid, if we can successfully program a cell directly within a patient, the entire landscape and treatment paradigm for cancer and many other diseases changes overnight. We are therefore, putting a lot of our internal emphasis towards such an outcome and executing on plans to bring this innovation to cancer patients within 12 months.     Daniel Getts, PhD Chief Executive Officer, Co-founder Board Director Dr. Getts is co-founder and CEO, of Myeloid Therapeutics, Cambridge, Massachusetts. He has led Myeloid since its founding and scaled it into a Company with multiple clinical products and a deep preclinical pipeline within three years of founding. Prior to Myeloid, Dr. Getts was VP of Research at TCR2, where he was a member of the leadership team that guided the company successfully through a series B ($120M) financing and an IPO (~$80M). Dr. Getts primary duties included leading the company’s target discovery, preclinical and translational research programs. These efforts resulted in numerous patent applications, a robust pipeline and a successfully filed IND. Prior to TCR2, Dr. Getts was primary inventor, founder and Chief Scientific Officer of Cour Pharmaceuticals Development Company, a nanotechnology platform company focused on autoimmunity and inflammation. As a member of the Cour leadership team he assisted in the negotiation of a number of pharmaceutical company collaborations and licenses, including with Takeda, who ultimately licensed TIMP-GLIA for $420M plus royalties. Prior to Cour, Dr. Getts was the Director of Research & Development at Tolera Therapeutics where he was the lead immunologist responsible for advancing the company’s monoclonal T cell antibody program from discovery through to Phase 3. A recipient of numerous honors and awards, including >10 issued patents and many more pending patent applications. Daniel is widely published with >45 peer-reviewed publications, with seminal publications in Nature Biotechnology, Science Translational Medicine and Nature Communications. He completed his Postdoctoral training in Stephen D. Miller’s laboratory at Northwestern University. He holds a PhD in Medicine from the University of Sydney and an MBA from Western Michigan University.

Read more


Delivering on the Promise of New Modalities: An Interview with Amber Van Laar, VP Clinical Development of AskBio

As part of WuXi AppTec’s ongoing efforts to collaboratively foster new thinking and actionable approaches in advancing breakthroughs for patients, we have launched a new interview series in 2022 – “Delivering on the Promise of New Modalities” – so leading voices of R&D can share how their approaches are addressing the barriers standing in the way of breakthroughs. For our next interview in this series, Amber Van Laar joins us as VP Clinical Development, CNS Gene Therapy of Asklepios Biopharmaceutical (AskBio) to shed light on neurodegenerative disease drug development. AskBio is a company dedicated to develop AAV (adeno-associated virus) based gene therapies for neuromuscular, central nervous system, cardiovascular, metabolic and other disorders. Last year, the company received FDA fast track designation for a novel investigational gene therapy for the treatment of a rare muscular dystrophy with no approved therapies. AskBio is also most notably working on a gene therapy for Parkinson’s Disease, and a gene therapy treating late-onset Pompe disease. One of the leading candidates of AskBio is focusing on Parkinson’s disease. From your perspective, why the treatment for Parkinson’s disease remains challenging? Amber: That’s a good question. To me, non-motor symptoms of Parkinson’s disease such as cognitive impairment, constipation, and depression can be more troublesome to patients than the classical motor symptoms, like tremors or slowness of movement. However, effective symptom management is not adequately addressed by currently available therapies. Further development is needed, particularly for preventative therapies, to evade these complicating and troublesome disease features. The lack of disease-modifying therapies remains a key challenge for patients and researchers, though many promising studies are underway. Close collaboration with regulatory agencies will be critical in order to establish a clear path to agreement on what measures are needed to define disease modification which are meaningful for both regulators and the Parkinson’s community. What are the opportunities for novel technologies to solve these challenges? What’s AskBio’s unique approach? Amber: The safe and accurate neurosurgical drug delivery directly to specific brain regions or neuronal networks has been rapidly evolving to overcome the pre-existing challenges of unmonitored “black box” administration of drugs intracranially. Direct visualization via MRI-monitored drug delivery to the brain was a significant technological leap that now allows neurosurgeons to dose drugs directly, accurately and consistently in brain regions impacted by a particular disease. At AskBio, our Parkinson’s program utilizes direct, MRI-guided delivery of AAV2-GDNF (glial cell-line derived neurotrophic factor) to evaluate the potential of this technology to overcome the challenges of variable delivery which may have contributed to the lack of significant responses observed in prior studies investigating either recombinant GDNF protein delivery or gene therapy approaches for Parkinson’s Disease. We believe that these improvements in delivery are crucial to accurately dose gene therapy to demonstrate a clinical effect, particularly for a neurotrophic growth factor like GDNF. Great. As your platform evolves, how to realize its full potential? What are the key elements for success? Amber: Delivering a new therapeutic platform at scale, particularly for the central nervous system and other disorders requiring specialized delivery, is a challenge on the horizon for cell and gene therapies.  The incorporation of robotic-assisted procedures, portable MRI scanners, and improved delivery devices will be needed to expedite procedures and reduce the resource intensiveness of the current procedure. Alongside the evolution of the surgical procedure, the development of cell and gene therapy centers of excellence will be needed to adequately train and disseminate this new technology beyond a limited number of highly trained neurosurgeons at major academic centers. Additionally, an early dialogue with payers and health agencies is needed for these advanced therapies to facilitate the post-approval path for one-time delivery of potential disease-modifying drugs. Aspects of neurosurgical delivery and the combined use of drug and novel devices further complicate this process, necessitating preemptive discussions with stakeholders to efficiently bring these novel therapies to patients. How do you see the field of gene therapy evolve in the next 10 years? Will gene therapy become the mainstream of new drugs approved? Amber: The approval path in the field of gene therapy has been embarked on by a few sponsors since 2015. The approval process of gene therapies is fraught with hurdles given the manufacturing requirements and the high bar these treatments are expected to achieve. The potential for one-time delivery of gene therapy and unknown long-term effects are additional factors that have prudently been raised as factors needed for the rigorous evaluation of gene therapies. The number of new INDs for gene therapies has sharply risen over the past five years, attesting to the promise that this technology holds. Given lengthy drug development timelines, and challenges with diseases like neurodegenerative disorders, I believe many of these studies may not achieve approval by 2030. This field is in its advent, and with only a few approval successes to provide guidance to subsequent studies. Learnings from future approvals will provide clarity on the rigorous gene therapy approval process for sponsors and regulators. As the regulatory path becomes more trodden, and with further refinement of this powerful technology, gene therapy is on course to open the door to a new modality of treating previously untreatable diseases. Anything else that may evolve over time in your view as we look towards 2030? Amber: The ability to reduce the cost of approvals in half by 2030 may be achievable in select drug development spaces. I believe these savings would not be anticipated for areas like cell and gene therapy. The novelty of cell and gene therapy and the potential of these therapies hold to change the direction of medicine are factors limiting cost and time savings in the early days of cell and gene therapy development. But I believe the utilization of decentralized trial designs, streamlined clinical development strategies, and the implementation of remote monitoring of participants in a real-world setting will hold the potential to reduce the overall costs of bringing drugs to approval. Thank you so much for your time, really appreciate your insights. Amber: My pleasure.     Amber D. Van Laar, MD VP Clinical Development, CNS Gene Therapy, Asklepios Biopharmaceutical Inc. (AskBio) Dr. Amber Van Laar obtained her MD from the University of Pittsburgh School of Medicine, followed by residency training in Neurology and a clinical-research fellowship in Movement Disorders at the University of Pittsburgh Medical Center. She later joined the department as an Assistant Professor in the Movement Disorders Division. As a physician-scientist, Dr. Van Laar continued her academic research in the Pittsburgh Institute for Neurodegenerative Diseases and received formal clinical research training through the Institute of Clinical Research Education at the University of Pittsburgh. Since 2002, Dr. Van Laar has researched gene therapy approaches for Parkinson’s disease and received the Clinician-Scientist Development Award from the Parkinson’s Foundation and the American Academy of Neurology to investigate the therapeutic potential of parkin gene therapy in parkinsonian rodent models. Dr. Van Laar has also been an investigator in clinical trials for neurodegenerative diseases, including multiple gene therapy studies for Parkinson’s disease.  Through volunteer work with local PD support groups and service on the Board of Directors for the Parkinson’s Foundation of Western Pennsylvania, she continues to contribute to the Parkinson’s disease community. Dr. Van Laar continues her work with gene therapy and now serves as the VP of Clinical Development for CNS Gene Therapy at Asklepios BioPharmacetuical Inc. (AskBio). She brings a unique blend of preclinical, clinical, and clinical-trial development experience to the advancement of gene therapy as a new platform to address the underlying causes of Parkinson’s disease and similar brain diseases.

Read more


Delivering on the Promise of New Modalities: An Interview with Kunwoo Lee, Ph.D., CEO of GenEdit

As part of WuXi AppTec’s ongoing efforts to collaboratively foster new thinking and actionable approaches in advancing breakthroughs for patients, we have launched a new interview series in 2022 – “Delivering on the Promise of New Modalities” – so leading voices of R&D can share how their approaches are addressing the barriers standing in the way of breakthroughs. Up next in this interview series, Kunwoo Lee shares his insight as CEO of GenEdit. His company is focusing on developing targeted in vivo delivery platform technologies for genetic medicines, and recently secured $26 million in Series A financing. GenEdit is currently developing innovative therapeutics targeting the nervous system, treating a range of diseases with high unmet medical need. Earlier this year, GenEdit announced its collaboration with Sarepta Therapeutics to develop gene editing therapeutics for the treatment of neuromuscular diseases. Congratulations on your recent progress, Kunwoo! What do you see as the major hurdles for genetic medicines? Kunwoo: From our point of view, the top three challenges for genetic medicines are delivery, delivery and delivery. The potential to treat the underlying causes of genetic and sporadic diseases with genetic medicines is unprecedented – gene therapy, gene silencing, gene editing and others – but these technologies are only useful as therapeutics if they can reach the affected tissues and cells. Current delivery options are limited. We categorize the main challenges as tissue selectivity, payload flexibility, ability to re-dose and ease of manufacturing. In addition, safety has become a significant concern. A better delivery system would be truly enabling for genetic medicine to reach its potential. How GenEdit plans to solve these challenges? What’s your technology and how it is differentiated? Kunwoo: We believe that solving the delivery challenge requires new materials and a systematic approach. At GenEdit, we are overcoming this challenge with our proprietary technology, NanoGalaxy. This platform is composed of hydrophilic polymers, which can have diverse interactions compared to hydrophobic systems. By systematically screening a diverse library, we are able to analyze structure-activity relationships (SAR) which identifies structures and properties contributing to tissue selective delivery. Computational SAR and iterative screening accelerate the development of tissue-selective polymers. NanoGalaxy is differentiated as it can deliver various genetic medicine payloads to tissues outside the liver from siRNA to mRNA beyond the size which adeno-associated virus (AAV) packing capacity has demonstrated. On top of that, the hydrophilic polymer can encapsulate various CRISPRs in ribonucleoprotein form, which is a unique feature. Do you see any potential risks and challenges associated with your approach? Kunwoo: Of course. We are developing a novel technology that has never been tested in humans and we understand that we have many challenges. One of our more interesting challenges is really an opportunity: our platform has the potential to be used to develop therapeutics for an enormous range of diseases. But we can’t do everything as a small company. Our solution is to focus on indications where the risk falls as much as possible onto our delivery technology and there is as little risk as possible for the target and payload. As our hydrophilic polymer nanoparticles are novel materials, we plan to engage with the FDA early in order to de-risk. Each validating milestone will enable new applications of the NanoGalaxy platform. Gazing into our crystal ball, what’s the future for genetic medicines? Say 2030? Kunwoo: We are focused on the future of genetic medicines and believe that they will be the mainstream of therapeutics in 2030. We are seeing an emergence of various genetic medicine candidates, including antisense oligonucleotide, siRNA, mRNA, new RNA systems, and CRISPRs. Eventually, in vivo genetic medicine will be generated from the combination of payload and delivery technology. Industry wide, how genetic medicines would transform the current R&D landscape? Kunwoo: The FDA had predicted 10-20 new approvals of gene therapies per year by 2025. The success will be dependent on platforms that are widely applicable and manufacturable. This is a goal which is not easy to achieve based on the current challenges that this industry is facing. Still, there is huge room for improvement in delivery technology regarding tissue selectivity, toxicity, immunogenicity, and manufacturing cost. At the same time, these new platforms are trying to address those challenges. In the end, a safer, cost-effective, and targeted delivery technology would overcome these limitations and could support 100+ approvals per year at half of today’s costs. Thank you Kunwoo for sharing your insights! We with you great success in future endeavors. Kunwoo: Thanks for inviting me. Enjoyed the discussion.     Kunwoo Lee, Ph.D. CEO, GenEdit Kunwoo has been CEO of GenEdit since he founded the company in 2016. He saw that the potential of genetic medicine was held back by the limitations of delivery technology, and the company’s NanoGalaxy platform enables the systematic and iterative screening of polymer-based vectors. He published several high-profile papers in Nature journals that demonstrated delivery of mRNA, protein therapeutics, and CRISPR-Cas9 and CRISPR-Cas12a; and he has 10 patent filings, including the company’s core polymer nanoparticle technology. Prior to GenEdit, he completed graduate research at UC Berkeley and UCSF in the Department of Bioengineering, where he focused on novel delivery systems for macromolecular therapeutics. He was named as a Forbes 30 under 30 in 2017 and was a Siebel Scholar in 2016.

Read more


Delivering on the Promise of New Modalities: An Interview with Ray Tabibiazar, M.D., CEO & Chairman of SalioGen Therapeutics

As part of WuXi AppTec’s ongoing efforts to collaboratively foster new thinking and actionable approaches in advancing breakthroughs for patients, we have launched a new interview series in 2022 – “Delivering on the Promise of New Modalities” – so leading voices of R&D can share how their approaches are addressing the barriers standing in the way of breakthroughs. Up next in our interview series, Ray Tabibiazar, M.D., a seasoned executive in the healthcare and biopharma industries, imparts his perspective as CEO & Chairman of SalioGen Therapeutics. SalioGen is advancing a new category of genetic medicine through its unique Gene Coding approach, a genome engineering technology that leverages proprietary mammal-derived enzymes. Earlier this year, SalioGen closed a $115 million Series B financing to advance the company’s goals of transforming the treatment paradigm for patients with inherited diseases and beyond. Thank you for taking the time to sit down with us, Ray. What major bottlenecks or barriers is SalioGen aiming to address? Ray: At SalioGen, we aim to address inherited disorders by addressing some of the limitations of currently available approaches. Current therapeutic approaches include gene editing and viral vector-based gene therapies. These modalities, however, often have limited clinical applicability. Many of the inherited disorders are caused by many different mutations and oftentimes involve a large gene (>5 kb sequence). Gene editing is designed to fix only a few point mutations at a time, and viral gene therapies can only accommodate gene sequences of a few thousand base pairs at most. Additionally, viral gene therapies carry the risk of causing potentially severe immune responses in patients and gene editing carries the risk of causing damage to the DNA that it changes. Altogether, the field of genetic medicine is limited in the number of inherited disorders it can address effectively and safely. How is SalioGen’s approach differentiated and what might be advantages of the approach? Ray: SalioGen is developing a new category of genetic medicine called Gene Coding, which is designed to turn on, turn off or modify the function of any gene in the genome. The cornerstone of Gene Coding is SalioGen’s portfolio of mammal-derived enzymes collectively called Saliogase, which can take a DNA sequence of any length and integrates it into the genome at a precise, pre-defined location. To our knowledge, SalioGen is the only company developing a mammalian genome engineering enzyme. Gene Coding machinery is delivered using a cell specific lipid nanoparticle; therefore, we don’t anticipate any risk of causing the virus-related immune responses that some gene therapies can cause. Furthermore, Saliogase works without causing double-stranded breaks when it inserts new DNA to the genome. It therefore doesn’t trigger any of the error-prone DNA repair pathways that may cause DNA damage and other unwanted downstream effects. Saliogase can also insert DNA sequences of any length, unlocking the potential to address most inherited disorders regardless of the size of the gene or genes involved in the disease. All these features are designed to make Gene Coding applicable to a broad range of inherited disorders. The physical components of the technology are also easily reproducible and scalable, ensuring they can be manufactured to reach large patient populations with prevalent inherited disorders. What challenges are you facing currently and how are you addressing these?  Ray: With the recent explosion of new biotech companies, there has been a shortage across the sector including limited capacity at partner CDMOs and a shortage of non-human primates for GLP toxicology studies. We are working to develop in-house CMC capabilities to maintain control over our manufacturing process. Pipelines of genetic medicines are on the rapid rise. What trends do you see coming in the next few years?  Ray: There has been a clear trend toward the accelerated development timeline for the new fields in genetic medicine. RNA-based therapeutics were largely developed over the course of roughly the past twenty years, with siRNA therapeutics and recently with mRNA therapeutics. On the other hand, the more recent newcomer of gene editing has taken hold in about half the time, in the past 11 years since the first papers on the CRISPR-Cas9 system as we know it were first published. We anticipate that by 2030, we’ll see increased availability of different modalities of genetic medicine for inherited disorders. In addition to currently available products like viral vector-based gene therapies, RNAi and antisense oligonucleotides, perhaps modalities like Gene Coding and other non-viral genome modification platforms, mRNA-based gene therapies and epigenetic therapies will be further advanced and available for patients. Definitely a great outlook and great opportunities for patients.  Any closing thoughts you like to share with our audience? Ray: Looking forward, we expect to see a shift in drug approvals away from single-purpose compounds and toward therapies based on platform technologies. Successful platform technologies will each be capable of yielding multiple successful therapies, each of which can be developed in parallel. Platform technology-based development is becoming more common and is significantly more streamlined than the historically more common trial-and-error, one-molecule-at-a-time path of drug development, and that may push us toward a greater volume of drug approvals by 2030. Thank you Ray, it’s been an insightful discussion into the new breakthroughs SalioGen is bringing to the field of genetic medicine. We wish you luck in your future endeavors. Ray: Thanks for having me.   Ray Tabibiazar CEO & Chairman, SalioGen Therapeutics Ray is a seasoned executive with leadership experience in the healthcare and biopharma industries, including venture capital, pharmaceuticals and diagnostics. As a clinician-entrepreneur and as managing director of 526 Ventures, he has focused on creating new ventures in the form of new companies or spinouts to translate innovative science into commercially viable products. Previously, Ray led Aravive Biologics as President and CEO, served as Senior Vice President, Corporate Development and Business Strategy at Twist Bioscience, a venture partner at Bay City Capital, and other senior executive roles. Prior to moving to industry, Ray was a practicing cardiologist and an adjunct faculty member at Stanford University, having trained as a physician scientist at Harvard Medical School and a cardiologist at Stanford Medical Center. Ray graduated with his medical degree from Harvard Medical School.

Read more


Delivering on the Promise of New Modalities: WuXi AppTec Interview Series

As part of WuXi AppTec’s ongoing efforts to collaboratively foster new thinking and actionable approaches in advancing breakthroughs for patients, we have launched a new interview series in 2022 – “Delivering on the Promise of New Modalities” – so leading voices of R&D can share how their approaches are addressing the barriers standing in the way of breakthroughs. Zachary Hornby President & CEO, Boundless Bio Nikole Kimes CEO & Co-Founder, Siolta Therapeutics Reagan Jarvis Co-Founder & CEO, Anocca AB Geoff Hamilton Co-Founder & CEO, Stemson Therapeutics Yann Chong Tan Founder & CEO, Nuevocor George Wu Co-Founder & CEO, Amberstone Biosciences Andrea van Elsas CSO, Abata Therapeutics Elvire Gouze CEO & Founder, Innoskel SAS, France Mark Frohlich CEO, Indapta Therapeutics Karen Kozarsky Co-Founder & Chief Scientific Officer, SwanBio Therapeutics James McArthur President & CEO, PepGen Daniel Getts CEO, Co-Founder & Board Director, Myeloid Therapeutics Amber Van Laar VP Clinical Development, AskBio Kunwoo Lee CEO, GenEdit Ray Tabibiazar CEO & Chairman, SalioGen Therapeutics David Main President & CEO, Notch Therapeutics Susan Dillon CEO, Aro Biotherapeutics

Read more